Q4 Pipeline Update

Q4 Pipeline Update

Kantify reports key scientific advances across its neurology and oncology programs this quarter.

Central Nervous System / Essential Tremor - CaV3.1

Lead compounds showed robust in vitro and ex vivo activity, reinforcing the mechanistic basis of the program and supporting progression to in vivo studies.

Oncology / Soft Tissue Sarcoma

Our oncology pipeline advanced with positive in vivo antitumor efficacy in soft-tissue sarcoma models, confirming the potential of our AI-selected candidates and the underlying targets.

“Sapian’s AI-driven drug discovery delivered lead-series compounds for two distinct therapeutic indications in an unusually short timeframe.”
— Nicolas Maignan, COO

For partnering inquiries or further information, please contact us via the website form.

About Kantify
Kantify is a small molecule drug-discovery company that applies proprietary AI models to identify safe and selective medicines in diseases where patients are in need for effective treatments.